» Articles » PMID: 25109354

CIP2A Regulates Cell Proliferation Via the AKT Signaling Pathway in Human Lung Cancer

Overview
Journal Oncol Rep
Specialty Oncology
Date 2014 Aug 12
PMID 25109354
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Cancerous inhibitor of PP2A (CIP2A) is an intracellular endogenous protein phosphatase 2A (PP2A) inhibitor with oncogenic activities. Initially identified as a tumor-associated antigen (TAA) in gastric and liver cancer patients, CIP2A was overexpressed in a variety of cancer types. The overexpression of CIP2A in cancer cells is associated with increased cell proliferation. However, the mechanism of CIP2A in cancer cell proliferation remains poorly understood. In the present study, we reported that CIP2A can regulate AKT phosphorylation at S473 under growth factor stimulation and our results also showed that CIP2A may promote cell proliferation through the AKT signaling pathway. Notably, depletion of CIP2A did not induce a global change of AKT phosphatase activity, which indicated that CIP2A may recognize specific AKT targets and play certain roles in the signaling pathway. In addition, we detected that CIP2A expression was associated with mTOR phosphorylation. Our further analysis corroborated the relationship between CIP2A and AKT-mTOR signaling pathway. Therefore, our study addressed a novel role of CIP2A in mediating cancer progression through interacting with the AKT-mTOR signaling pathway.

Citing Articles

CIP2A promotes bronchiolitis obliterans by activating the NF‑κB pathway.

Zhou X, Zhao X, Li Y, Zhang B Mol Med Rep. 2025; 31(4).

PMID: 40017141 PMC: 11881678. DOI: 10.3892/mmr.2025.13473.


CIP2A interacts with AKT1 to promote the malignant biological behaviors of oral squamous cell carcinoma by upregulating the GSK‑3β/β‑catenin pathway.

Che Y, Zhang H, Li H, Wu X Exp Ther Med. 2023; 26(5):514.

PMID: 37840566 PMC: 10570767. DOI: 10.3892/etm.2023.12213.


From Basic Science to Clinical Practice: The Role of Cancerous Inhibitor of Protein Phosphatase 2A (CIP2A)/p90 in Cancer.

Chen B, Hu H, Chen X Front Genet. 2023; 14:1110656.

PMID: 36911405 PMC: 9998691. DOI: 10.3389/fgene.2023.1110656.


Is Nucleoredoxin a Master Regulator of Cellular Redox Homeostasis? Its Implication in Different Pathologies.

Idelfonso-Garcia O, Alarcon-Sanchez B, Vasquez-Garzon V, Baltierrez-Hoyos R, Villa-Trevino S, Muriel P Antioxidants (Basel). 2022; 11(4).

PMID: 35453355 PMC: 9030443. DOI: 10.3390/antiox11040670.


Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression.

Xue C, Li G, Lu J, Li L Signal Transduct Target Ther. 2021; 6(1):400.

PMID: 34815385 PMC: 8611092. DOI: 10.1038/s41392-021-00788-w.


References
1.
Alayev A, Holz M . mTOR signaling for biological control and cancer. J Cell Physiol. 2013; 228(8):1658-64. PMC: 4491917. DOI: 10.1002/jcp.24351. View

2.
Soo Hoo L, Zhang J, Chan E . Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene. 2002; 21(32):5006-15. DOI: 10.1038/sj.onc.1205625. View

3.
Come C, Laine A, Chanrion M, Edgren H, Mattila E, Liu X . CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res. 2009; 15(16):5092-100. DOI: 10.1158/1078-0432.CCR-08-3283. View

4.
Ren X, Sato Y, Harada K, Sasaki M, Furubo S, Song J . Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat. PLoS One. 2014; 9(1):e87660. PMC: 3907540. DOI: 10.1371/journal.pone.0087660. View

5.
Huang L, Adelson M, Mordechai E, Trama J . CIP2A expression is elevated in cervical cancer. Cancer Biomark. 2011; 8(6):309-17. DOI: 10.3233/CBM-2011-0220. View